A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
Trial details
- Registry ID
- NCT06302348
- Drugs studied
- Sepiapterin
TrialRedline tracks 16 clinical trials sponsored by PTC Therapeutics: 7 Phase 3, 4 Phase 2 / 3, 5 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Sepiapterin in Participants With Phenylketonuria (PKU)NCT06302348 | Sepiapterin | Recruiting | 2031-02-28Estimated |
| A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich AtaxiaNCT05515536 | Vatiquinone | Active not recruiting | 2027-12-31Estimated |
| A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaNCT05166161 | PTC923 | Completed | 2026-07-21Actual |
| A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseaseNCT05218655 | Vatiquinone | Completed | 2025-04-15Actual |
| A Study of PTC923 in Participants With PhenylketonuriaNCT05099640 | PTC923 | Completed | 2023-04-03Actual |
| Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyNCT03179631 | Ataluren | Completed | 2022-03-05Actual |
| Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)NCT01247207 | Ataluren | Terminated | 2026-02-10Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaNCT04577352 | Vatiquinone | Completed | 2023-04-04Actual |
| A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)NCT05269355 | Dacarbazine, Unesbulin | Terminated | 2024-06-17Actual |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyNCT04378075 | Vatiquinone | Terminated | 2023-03-18Actual |
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)NCT04439071 | PTC299, SOC | Terminated | 2022-07-20Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric ParticipantsNCT04903288 | Eladocagene Exuparvovec | Active not recruiting | 2023-05-22Actual |
| A Study of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaNCT05485987 | Vatiquinone | Completed | 2024-08-29Actual |
| Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh SyndromeNCT02352896 | EPI-743 | Completed | 2023-10-30Actual |
| A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)NCT04336826 | Ataluren | Completed | 2023-08-07Actual |
| Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALSNCT05349721 | PTC857 | Terminated | 2024-09-26Actual |
Names as written in the registry records.
NCT01247207 · PTC Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants With Adverse Events Time frame: Baseline up to end of study (up to approximately 8 years) Measure: Number of Participants With Laboratory Parameters Abnormalities Description: Laboratory parameters include hematological, serum biochemistry, adrenal laboratories, and urine data. Time frame: Baseline up to end of study (up to approximately 8 years) Measure: Number of Participants With Abnormal Physical Findings Description: Physical findings include weight, physical examination data, systolic and diastolic blood pressure, radial pulse rate, and body temperature. Time frame: Baseline up to end of study (up to approximately 8 years). After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred or worsened on or after the first dose of ataluren and up to 4 weeks after the last dose of ataluren. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. Time frame: Baseline up to end of study (up to approximately 15 years).
Before: Estimated. After: Actual.
Before: 270 participants (planned). After: 265 participants (actual).
Before: Completed. After: Terminated.
NCT05166161 · PTC Therapeutics
Before: Estimated. After: Actual.
Before: 200 participants (planned). After: 247 participants (actual).
Before: Estimated. After: Actual.
Before: 30 Jun 2026. After: 21 Jul 2026.
Before: Active not recruiting. After: Completed.
NCT04577352 · PTC Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change From Baseline in the Modified Friedreich Ataxia Rating Scale (mFARS) Score at Week 72. After: Measure: Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set Measure: Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures per 28 Days. After: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period.
NCT01247207 · PTC Therapeutics
Before: Estimated. After: Actual.
Before: 30 Apr 2025. After: 10 Feb 2026.
Before: Enrolling by invitation. After: Completed.
NCT05166161 · PTC Therapeutics
Before: 30 Apr 2026. After: 30 Jun 2026.
Before: Recruiting. After: Active not recruiting.
NCT03179631 · PTC Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Slope of Change in 6-Minute Walk Distance (6MWD) Over 72 Weeks. After: Measure: DB Period: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 72 - Modified Intention-to-treat (mITT) Population Measure: DB Period: Change From Baseline in 6MWD at Week 72 - Intent-to-Treat (ITT) Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - mITT Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - ITT Population.
NCT05218655 · PTC Therapeutics
Before: 102 participants (actual). After: 101 participants (actual).
NCT05218655 · PTC Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants With Adverse Events (AEs). After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs).